TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06118086: Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

Sponsor: Remix Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 125 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$5,772,690

Rescue Site Savings

+$3,809,190

Unlock Full NCT06118086 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06118086 Rescue Dossier →